The rates of life-threatening breast cancer are spiking among women of all ages, with a significant increase in those under ...

Patients with ER-positive/HER2-negative metastatic breast cancer who received elacestrant experienced a significant reduction ...

While under competitive pressure from Novartis and Eli Lilly, Pfizer can tally up a unique trial win for its Ibrance in a ...

Alliance Foundation Trials, LLC (AFT) and Pfizer Inc. today announced results from the phase III PATINA trial demonstrating that the addition of palbociclib (IBRANCE) to current standard-of-care first ...

A professor at the University of Illinois is pioneering cancer research that could curb tumor growth. Erik Nelson is an ...

Alliance Foundation Trials, LLC (AFT) and Pfizer Inc. today announced results from the phase III PATINA trial demonstrating ...

The event will be webcast live and can be accessed by visiting the Investors section of ALX Oncology's website at ...

Eli Lilly LLY announced results from the phase III EMBER-3 study, which showed that treatment with its orally administered ...

ADELA, an international phase III study being conducted across multiple countries, combines elacestrant with everolimus to ...

Praise Is The Cure, a faith-based breast cancer awareness program for Black women, also reaches out to the men who have been ...

Arvinas, Pfizer announce initial phase 1b data from the TACTIVE-U sub-study of vepdegestrant in combo with abemaciclib at 2024 SABC symposium: New Haven, Connecticut Thursday, Dec ...

AstraZeneca and MSD's PARP inhibitor Lynparza has improved long-term survival when given as adjuvant therapy for early breast ...